NCT03336541 is a Phase 4 clinical trial of Ketamine in Perinatal Depression, sponsored by Peking University First Hospital.

Who is sponsoring NCT03336541?

NCT03336541 is sponsored by Peking University First Hospital.

What drugs are being tested in NCT03336541?

Interventions in NCT03336541: Ketamine, Placebo.

What condition does NCT03336541 study?

NCT03336541 studies Perinatal Depression, Ketamine, Cesarean Delivery, Postpartum Depression.

Is NCT03336541 still recruiting?

NCT03336541 is currently completed. Last updated 13 December 2021.

Last reviewed 2021-12-13 · How we verify

NCT03336541

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-dose Ketamine and Postpartum Depression in Parturients With Prenatal Depression

Completed Phase 4 Last updated 13 December 2021

What this trial tests

Phase 4 trial testing Ketamine in Perinatal Depression in 64 participants. Completed in 25 June 2018.

Timeline

23 November 2017

Primary endpoint
14 May 2018

25 June 2018

Quick facts

Lead sponsor	Peking University First Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	64
Start date	23 November 2017
Primary completion	14 May 2018
Estimated completion	25 June 2018
Sites	1 location across China

Drugs / interventions tested

Ketamine (ketamine) — full drug profile →
Placebo

Conditions studied

Perinatal Depression — all drugs for Perinatal Depression →
Ketamine — all drugs for Ketamine →
Cesarean Delivery — all drugs for Cesarean Delivery →
Postpartum Depression — all drugs for Postpartum Depression →

Sponsor

Peking University First Hospital

Who can join

Adults 18 to 45, female only, with Perinatal Depression or Ketamine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Postpartum depression is common in mothers early after childbirth and produces harmful effects not only on mothers, but also on infants and young children. Parturients with prenatal depression are at increased of postpartum depression. Low-dose ketamine can be used for antidepressant therapy. We hypothesize that low-dose ketamine has a therapeutic effect on parturients with prenatal depression. This study is designed to investigate whether low-dose ketamine administered during cesarean delivery can decrease the incidence of postpartum depression in parturients with prenatal depression.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Single low-dose ketamine infusion for women with prenatal depressive symptoms undergoing cesarean delivery: A pilot randomized trial.
Wang S, Deng CM, Zeng Y, Ma JH, et al · · 2022 · cited 10× · PMID 36570810 · DOI 10.3389/fsurg.2022.1050232
Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.
Vasiliu O. · · 2022 · cited 9× · PMID 35847011 · DOI 10.3389/fphar.2022.884155

Verify or expand the search:

Other trials of Ketamine

Trials testing the same drug.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT06963294 — Ketamine and Dexmedetomidine for Delirium in Joint Arthroplasty · NA · not yet recruiting
NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07197684 — Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surg · NA · not yet recruiting
NCT06231563 — Ketamine for Veterans With Parkinson's Disease · Phase 2 · recruiting

Other recruiting trials for Perinatal Depression

Currently open trials in the same condition.

NCT06790641 — Pathways to Perinatal Mental Health Equity · NA · recruiting
NCT06968390 — Accelerated TMS for Perinatal Depression · NA · recruiting
NCT06594263 — Validation of the French Version of the Perinatal Assessment of Paternal Affectivity (PAPA) · recruiting
NCT06364488 — TrueBlue Clinical Study - Investigating the Use of a Mobile Phone App TrueBlue for Monitoring Depression and Anxiety · NA · recruiting
NCT06473935 — Maternal Well-being in the Perinatal Period · recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03336541 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 13 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03336541.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing